Elbasvir–Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy
Gregory J. Dore(UNSW Sydney), Heather Platt(Merck & Co., Inc., Rahway, NJ, USA (United States)), David C. Nickle(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ronald Nahass, Oren Shibolet(Tel Aviv University), Jason Grebely(UNSW Sydney), Erluo Chen, Frederick L. Altice(Heidelberg University), Olav Dalgård(University of Oslo), Cheng‐Yuan Peng(China Medical University), Frank J. Dutko(Merck & Co., Inc., Rahway, NJ, USA (United States)), Alain H. Litwin(Prisma Health), Michael Robertson(Merck & Co., Inc., Rahway, NJ, USA (United States)), Anne F. Luetkemeyer(University of California, San Francisco), Edward Gane(University of Auckland), Eliav Barr(University of New Mexico), Janice Wahl, Brian Conway, Hsueh‐Cheng Huang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Isaias Noel Gendrano(Merck & Co., Inc., Rahway, NJ, USA (United States)), Anita Y. M. Howe(St. Paul's Hospital), Bach‐Yen Nguyen(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 364
Related Papers
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k
Mitotic and G <sub>2</sub> Checkpoint Control: Regulation of 14-3-3 Protein Binding by Phosphorylation of Cdc25C on Serine-216
|Science|1997|1.3k
ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES
|Unknown|2006|940